Lack of benefit of temozolomide for MGMT methylated patients with high vascular glioblastoma: a confirmatory study

María del Mar Álvarez-Torres, Elies Fuster-García, Carmen Balaña, Josep Puig, Juan Miguel García-Gómez
doi: https://doi.org/10.1101/2021.09.01.21262673

Article Information

doi 
https://doi.org/10.1101/2021.09.01.21262673
History 
  • September 3, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. María del Mar Álvarez-Torres*,1,
  2. Elies Fuster-García2,
  3. Carmen Balaña3,
  4. Josep Puig4 and
  5. Juan Miguel García-Gómez1
  1. 1Universitat Politècnica de València, ITACA, Biomedical Data Science Laboratory. Valencia, Spain
  2. 2Oslo University Hospital, Department of Diagnostic Physics. Oslo, Norway
  3. 3Institut Catala Oncologia Badalona. Barcelona, Spain
  4. 4Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta. Girona, Spain
  1. ↵*Correspondence: maaltor4{at}upv.es; Tel.: +34 669933613
Back to top
Posted September 03, 2021.
Download PDF
Data/Code
Email
Lack of benefit of temozolomide for MGMT methylated patients with high vascular glioblastoma: a confirmatory study
María del Mar Álvarez-Torres, Elies Fuster-García, Carmen Balaña, Josep Puig, Juan Miguel García-Gómez
medRxiv 2021.09.01.21262673; doi: https://doi.org/10.1101/2021.09.01.21262673
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area